Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies

Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies

In 2014, the survival benefits seen in REGARD and RAINBOW studies led the way for the regulatory approval of ramucirumab in the second line setting in oesophagogastric (OG) cancer. Trials of other drugs targeting the vascular endothelial growth factor (VEGF) pathway have met with mixed results but t...

Full description

Bibliographic Details
Main Authors: Oliver Butters, Kate Young, David Cunningham, Ian Chau, Naureen Starling
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Oncology
Subjects:
gastroesophageal cancer
vascular endothelial grow factor
immunotharapy
ramucirumab
biomarkers
bevacizumab
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00618/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00618/full

Similar Items